Log in

Relevant bibliographies by topics / Fibrosis and cirrhosis / Journal articles

To see the other types of publications on this topic, follow the link: Fibrosis and cirrhosis.

Journal articles on the topic 'Fibrosis and cirrhosis'

Author: Grafiati

Published: 5 June 2025

Last updated: 2 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Fibrosis and cirrhosis.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Sebay, Ahmed M. El, Pavel N. Abramov та Seidfatima M. Borunova. "Мolecular diagnosis of fibrotic and cirrhotic changes in the liver of dogs". Veterinariya, Zootekhniya i Biotekhnologiya 1, № 98 (2022): 24–33. http://dx.doi.org/10.36871/vet.zoo.bio.202201004.

Full text

Abstract:

Liver fibrosis or cirrhosis are major outcomes of long-standing chronic liver injury in which most dogs remain asymptomatic until fatal liver insufficiency is developed. The current study aimed to investigate if hepatocyte-derived cfa-miRNAs-21 and -200c can serve as new diagnostic serum biomarkers of the fibrotic and cirrhotic changes in dogs with chronic liver injury. On the basis of ultrasound, computed tomography and histopathological examination; twenty healthy dogs were included in the control group for comparison with dogs that were confirmed to have fibrosis or cirrhosi. Cfa-miRNA -20

APA, Harvard, Vancouver, ISO, and other styles

2

Che, Ying, Youjung Chien, Yuli Zhu, et al. "GSDMD-Dependent Neutrophil Extracellular Traps Mediate Portal Vein Thrombosis and Associated Fibrosis in Cirrhosis." International Journal of Molecular Sciences 25, no. 16 (2024): 9099. http://dx.doi.org/10.3390/ijms25169099.

Full text

Abstract:

Portal vein thrombosis (PVT) is a challenging and controversial complication of cirrhosis. Experimental models that reproduce cirrhotic PVT and effective pharmacological therapies are limited. We aimed to investigate the nature course and mechanisms of PVT in cirrhosis. A novel PVT model was developed via two-step total portal vein ligation in healthy and thioacetamide (TAA)-cirrhotic rats. Circulating and liver-infiltrating neutrophils were isolated from individuals with cirrhosis to examine neutrophil extracellular traps (NETs) and explore their unique characteristics and implications in PVT

APA, Harvard, Vancouver, ISO, and other styles

3

Chirapongsathorn, Sakkarin. "Stage and natural history of cirrhosis." Thai Journal of Hepatology 1, no. 2 (2018): 14–18. http://dx.doi.org/10.30856/th.jhep2018vol1iss2_04.

Full text

Abstract:

Cirrhosisis the final pathway of any chronic liver disease and can lead to a number of complications,including hepatocellular carcinoma. Liver fibrosis is the key role of disease progression in cirrhosis. Advanced liver fibrosis and early stage of cirrhosis are not usually clinically detectable or symptomatic.As patients develop more extensive hepatic fibrosis potentially resulting in development of cirrhoticcomplications such as variceal hemorrhage. Prognosis and survival is markedly better in patients with early stage of cirrhosis. Now there are many stages classification of cirrhosis define

APA, Harvard, Vancouver, ISO, and other styles

4

Moreau, Johanna, Pascaline Bouzy, Julien Guillard, et al. "Analysis of Hepatic Fibrosis Characteristics in Cirrhotic Patients with and without Hepatocellular Carcinoma by FTIR Spectral Imaging." Molecules 25, no. 18 (2020): 4092. http://dx.doi.org/10.3390/molecules25184092.

Full text

Abstract:

The evolution of cirrhosis is marked by quantitative and qualitative modifications of the fibrosis tissue and an increasing risk of complications such as hepatocellular carcinoma (HCC). Our purpose was to identify by FTIR imaging the spectral characteristics of hepatic fibrosis in cirrhotic patients with and without HCC. FTIR images were collected at projected pixel sizes of 25 and 2.7 μm from paraffinized hepatic tissues of five patients with uncomplicated cirrhosis and five cirrhotic patients with HCC and analyzed by k-means clustering. When compared to the adjacent histological section, the

APA, Harvard, Vancouver, ISO, and other styles

5

Chaopathomkul, Bundit, Ornalin Boonsirisak, and Krit Pongpirul. "Correlation of the Stiffness of Hepatocellular Carcinoma and Surrounding Liver Parenchyma by Point Shear Wave Elastography." Journal of Diagnostic Medical Sonography 35, no. 1 (2018): 10–15. http://dx.doi.org/10.1177/8756479318801587.

Full text

Abstract:

The purpose of this study was to assess the correlation between hepatocellular carcinoma (HCC) and surrounding liver parenchyma stiffness using point shear wave elastography (pSWE). HCC was diagnosed using the criteria of the American Association for the Study of Liver Diseases. Liver fibrosis was classified into three groups (nonsignificant fibrosis, significant fibrosis, and cirrhosis). pSWE was performed on the HCC and the adjacent hepatic parenchyma and was expressed as kilopascal (kPa). A total of 59 HCC patients with 64 tumors were included in the study. The mean stiffnesses of HCC and l

APA, Harvard, Vancouver, ISO, and other styles

6

Han, Man-Hoon, Jee Hyun Lee, Gyeonghwa Kim, et al. "Expression of the Long Noncoding RNA GAS5 Correlates with Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease." Genes 11, no. 5 (2020): 545. http://dx.doi.org/10.3390/genes11050545.

Full text

Abstract:

Background: Advanced liver fibrosis is the most important prognostic factor in nonalcoholic fatty liver disease (NAFLD). The long noncoding RNA (lncRNA), growth arrest-specific transcript 5 (GAS5), is associated with the inhibition of liver fibrogenesis, and its levels are decreased in cirrhotic liver. Methods: We analyzed 51 patients with NAFLD, the diagnosis of which was confirmed by liver biopsy. Expression of GAS5 in both the liver and plasma of the patients was analyzed using a quantitative real-time polymerase chain reaction according to the fibrosis stage. Results: Plasma GAS5 expressio

APA, Harvard, Vancouver, ISO, and other styles

7

Bravo, E., E. D'Amore, F. Ciaffoni, and C. L. Mammola. "Evaluation of the spontaneous reversibility of carbon tetrachloride-induced liver cirrhosis in rabbits." Laboratory Animals 46, no. 2 (2012): 122–28. http://dx.doi.org/10.1258/la.2012.011035.

Full text

Abstract:

There is a general consensus that liver fibrosis in humans is potentially reversible, while scepticism prevails on the concept that cirrhosis can be truly reversed. The availability of suitable experimental models is fundamental for disease research. The experimental murine model of liver cirrhosis induced by carbon tetrachloride (CCl4) reproduces both the histological picture of the postnecrotic cirrhosis and its biochemical and clinical parameters. Normal hepatic structure is modified by formation of regeneration nodules. Fibrosis represents a morphological element of disease and an effect o

APA, Harvard, Vancouver, ISO, and other styles

8

Lafoz, Erica, Genís Campreciós, Héctor García-Calderó, et al. "Impact of lifestyle interventions targeting physical exercise and caloric intake on cirrhosis regression in rats." American Journal of Physiology-Gastrointestinal and Liver Physiology 321, no. 6 (2021): G603—G616. http://dx.doi.org/10.1152/ajpgi.00191.2021.

Full text

Abstract:

We have developed two advanced cirrhosis regression experimental models with persistent relevant fibrosis and portal hypertension and an associated deteriorated metabolism that mimic what happens in patients. LI, despite improving metabolism, did not enhance the regression process in our cirrhotic models. CR did not further reduce PP, hepatic fibrosis, or HSC activation. MEE exhibited a profibrogenic effect in the liver blunting cirrhosis regression. One of the potential explanations of this worsening could be ammonia accumulation.

APA, Harvard, Vancouver, ISO, and other styles

9

Delgado, María Gabriela, Jordi Gracia-Sancho, Giusi Marrone, et al. "Leptin receptor blockade reduces intrahepatic vascular resistance and portal pressure in an experimental model of rat liver cirrhosis." American Journal of Physiology-Gastrointestinal and Liver Physiology 305, no. 7 (2013): G496—G502. http://dx.doi.org/10.1152/ajpgi.00336.2012.

Full text

Abstract:

Increased hepatic vascular resistance mainly due to elevated vascular tone and to fibrosis is the primary factor in the development of portal hypertension in cirrhosis. Leptin, a hormone associated with reduction in nitric oxide bioavailability, vascular dysfunction, and liver fibrosis, is increased in patients with cirrhosis. We aimed at evaluating whether leptin influences the increased hepatic resistance in portal hypertension. CCl4-cirrhotic rats received the leptin receptor-blocker ObR antibody, or its vehicle, every other day for 1 wk. Hepatic and systemic hemodynamics were measured in b

APA, Harvard, Vancouver, ISO, and other styles

10

Jian, Jianbo, Xinyan Zhao, Lili Qin, et al. "Three-dimensional visualization of fibrous tissues in cirrhotic rats via X-ray phase-contrast computed tomography with iodine staining." Journal of Synchrotron Radiation 26, no. 4 (2019): 1354–60. http://dx.doi.org/10.1107/s1600577519006064.

Full text

Abstract:

To accurately characterize cirrhosis, knowledge of the 3D fibrous structures is essential. Histology is the gold standard in cirrhosis screening, but it mainly provides structural information in 2D planes and destroys the 3D samples in the process. The aim of this study was to evaluate the potential of X-ray phase-contrast computed tomography (PCCT) with iodine staining for the 3D nondestructive visualization of internal structural details in entire cirrhotic livers with histopathologic correlation. In this study, cirrhotic livers induced by carbon tetrachloride (CCl4) in rats were imaged via

APA, Harvard, Vancouver, ISO, and other styles

11

Møller, S., M. Hansen, J. Hillingsø, J.-E. B. Jensen, and J. H. Henriksen. "Elevated carboxy terminal cross linked telopeptide of type I collagen in alcoholic cirrhosis: relation to liver and kidney function and bone metabolism." Gut 44, no. 3 (1999): 417–23. http://dx.doi.org/10.1136/gut.44.3.417.

Full text

Abstract:

BACKGROUNDThe carboxy terminal cross linked telopeptide of type I collagen (ICTP) has been put forward as a marker of bone resorption. Patients with alcoholic liver disease may have osteodystrophy.AIMSTo assess circulating and regional concentrations of ICTP in relation to liver dysfunction, bone metabolism, and fibrosis.METHODSIn 15 patients with alcoholic cirrhosis and 20 controls, hepatic venous, renal venous, and femoral arterial concentrations of ICTP, and bone mass and metabolism were measured.RESULTSCirculating ICTP was higher in patients with cirrhosis than in controls. No overall sign

APA, Harvard, Vancouver, ISO, and other styles

12

Orr, Christine E., Peter L. Wang, Lina Chen, and Tao Wang. "Features of fibrosis regression abound in “non-cirrhotic” patients with resected hepatocellular carcinoma." PLOS ONE 17, no. 5 (2022): e0267474. http://dx.doi.org/10.1371/journal.pone.0267474.

Full text

Abstract:

Cirrhosis is a major risk factor for developing hepatocellular carcinoma (HCC). However, many surgically resected HCCs are presumably non-cirrhotic. The dynamic nature of chronic liver disease leads to periods of hepatic repair and fibrosis regression. We hypothesize that most resected HCCs, including those from non-cirrhotic patients, exhibit features of fibrosis regression in their background liver, suggesting previously more advanced liver disease. We reviewed the histology of 37 HCC resections performed between 2005–2020, including 30 from non-cirrhotic patients. The non-neoplastic liver w

APA, Harvard, Vancouver, ISO, and other styles

13

Pereira-Filho, Gustavo, Clarissa Ferreira, Alex Schwengber, Cláudio Marroni, Cláudio Zettler, and Norma Marroni. "Role of N-acetylcysteine on fibrosis and oxidative stress in cirrhotic rats." Arquivos de Gastroenterologia 45, no. 2 (2008): 156–62. http://dx.doi.org/10.1590/s0004-28032008000200013.

Full text

Abstract:

BACKGROUND: Hepatic cirrhosis is the final stage of liver dysfunction, characterized by diffuse fibrosis which is the main response to the liver injury. The inhalatory carbon tetrachloride is an effective experimental model that triggers cirrhosis and allows to obtain histological and physiological modifications similar to the one seen in humans. AIM: To investigate the effects of N-acetylcysteine (NAC) on the fibrosis and oxidative stress in the liver of cirrhotic rats, analyzing liver function tests, lipoperoxidation, activity of glutathione peroxidase enzyme, collagen quantification, histop

APA, Harvard, Vancouver, ISO, and other styles

14

Peng, Li-jun, Jin-sheng Guo, Zhe Zhang, et al. "Polymorphisms of AZIN1 rs2679757 and TRPM5 rs886277 are Associated with Cirrhosis Risk in Chinese Patients with Chronic Hepatitis B." Infection International 1, no. 2 (2012): 103–9. http://dx.doi.org/10.1515/ii-2017-0016.

Full text

Abstract:

Abstract Objective Genome-wide association studies (GWAS) have linked many single nucleotide polymorphisms (SNPs) to the outcomes of a variety of liver diseases. The aim of the present study was to evaluate the association of several candidate SNPs with the risk and severity of cirrhosis due to chronic hepatitis B in a Chinese population. Methods A total of 714 Chinese participants with persistent HBV infection were studied. Patients were divided into cirrhotic (n = 429) and non-cirrhotic (n = 285) groups based on clinical and pathological evidence. The progression rate and severity of liver c

APA, Harvard, Vancouver, ISO, and other styles

15

Sánchez, Paula Sánchez, María del Mar Rigual, and Nabil Djouder. "Inflammatory and Non-Inflammatory Mechanisms Controlling Cirrhosis Development." Cancers 13, no. 20 (2021): 5045. http://dx.doi.org/10.3390/cancers13205045.

Full text

Abstract:

Because the liver is considered to be one of the most important metabolic organs in the body, it is continuously exposed to damaging environmental agents. Upon damage, several complex cellular and molecular mechanisms in charge of liver recovery and regeneration are activated to prevent the failure of the organ. When liver injury becomes chronic, the regenerative response goes awry and impairs the liver function, consequently leading to cirrhosis, a liver disorder that can cause patient death. Cirrhosis has a disrupted liver architecture and zonation, along with the presence of fibrosis and pa

APA, Harvard, Vancouver, ISO, and other styles

16

Boettler, Tobias, and Robert Thimme. "Antiviral Therapy in Hepatitis B Virus-Associated Liver Cirrhosis." Digestive Diseases 33, no. 4 (2015): 608–12. http://dx.doi.org/10.1159/000375357.

Full text

Abstract:

Background: Chronic hepatitis B virus (HBV) infection is a major risk factor for the development of liver cirrhosis and hepatocellular carcinoma (HCC). Key Messages: In patients with advanced liver fibrosis or liver cirrhosis, antiviral therapy is mandatory to slow down, halt or reverse disease progression and possibly reduce the risk of HCC development. As in patients without advanced fibrosis, PEG-interferon and nucleoside/nucleotide analogues (NUCs) are available for antiviral therapy. NUC therapy should be performed indefinitely as the rates of HBs-Ag loss are low. Entecavir or tenofovir s

APA, Harvard, Vancouver, ISO, and other styles

17

Fujita, Koji, and Tsutomu Masaki. "Serum Biomarkers of Liver Fibrosis Staging in the Era of the Concept “Compensated Advanced Chronic Liver Disease”." Journal of Clinical Medicine 10, no. 15 (2021): 3340. http://dx.doi.org/10.3390/jcm10153340.

Full text

Abstract:

Non-invasive indexes of liver fibrosis based on blood examinations have been developed for decades, partially replacing liver biopsy examinations. Recently, the concept of liver cirrhosis was revised and converted to “compensated advanced chronic liver diseases” since the Baveno VI consensus statement in 2015. The term “compensated advanced chronic liver diseases” was established based on the premise that serum biomarkers were not able to differentiate cirrhosis from severe fibrosis. The difficulty to histologically distinguish cirrhosis from severe fibrosis had been pointed out in 1977, when

APA, Harvard, Vancouver, ISO, and other styles

18

Giatromanolaki, Alexandra, Stamatia Kotsiou, Michael I. Koukourakis, and Efthimios Sivridis. "Angiogenic Factor Expression in Hepatic Cirrhosis." Mediators of Inflammation 2007 (2007): 1–4. http://dx.doi.org/10.1155/2007/67187.

Full text

Abstract:

The pathogenesis of fibrosis in hepatic cirrhosis remains obscure. This study examines the eventual role of angiogenic factors in the fibrotic process. A series of 55 cirrhotic livers was studied for the proliferation state of fibroblasts, and the expression of vascular endothelial growth factor (VEGF), thymidine phosphorylase (TP) and the basic and acidic fibroblast growth factor (bFGF, aFGF) in both fibroblasts and hepatic cells. The angiogenic and/or fibrogenic factors VEGF, TP, bFGF, and aFGF were clearly expressed in regenerative hepatocytes, but not in fibroblasts of diffuse hepatic fibr

APA, Harvard, Vancouver, ISO, and other styles

19

Zhang, Ting-Ting, Si-Si Ye, Jun Liang, and Li Bai. "Prognostic value of non-invasive fibrosis indices post-curative resection in hepatitis-B-associated hepatocellular carcinoma patients." Experimental Biology and Medicine 245, no. 8 (2020): 703–10. http://dx.doi.org/10.1177/1535370220914252.

Full text

Abstract:

The occurrence and acuteness of liver cirrhosis were strongly associated with the hepatocarcinogenesis and the prognosis of hepatocellular carcinoma (HCC). This study compared the prognostic significance of non-invasive fibrosis panel containing 15 indices in hepatitis-B-associated HCC patients’ post-curative resection. Four hundred and five consecutive hepatitis-B-related HCC patients who went through curative hepatectomy were investigated retrospectively. The multivariate Cox proportional hazard model was used to evaluate independent prognostic factors for overall survival (OS). The accuracy

APA, Harvard, Vancouver, ISO, and other styles

20

Moore, Landon L., Dongfeng Qu, Sripathi Sureban, et al. "From Inflammation to Oncogenesis: Tracing Serum DCLK1 and miRNA Signatures in Chronic Liver Diseases." International Journal of Molecular Sciences 25, no. 12 (2024): 6481. http://dx.doi.org/10.3390/ijms25126481.

Full text

Abstract:

Chronic liver diseases, fibrosis, cirrhosis, and HCC are often a consequence of persistent inflammation. However, the transition mechanisms from a normal liver to fibrosis, then cirrhosis, and further to HCC are not well understood. This study focused on the role of the tumor stem cell protein doublecortin-like kinase 1 (DCLK1) in the modulation of molecular factors in fibrosis, cirrhosis, or HCC. Serum samples from patients with hepatic fibrosis, cirrhosis, and HCC were analyzed via ELISA or NextGen sequencing and were compared with control samples. Differentially expressed (DE) microRNAs (mi

APA, Harvard, Vancouver, ISO, and other styles

21

Paulusch, Stefan, Sandra Kalthoff, Steffen Landerer, et al. "Regulation of uridine diphosphate-glucuronosyltransferase 1A expression by miRNA-214-5p and miRNA-486-3p." Epigenomics 13, no. 4 (2021): 271–83. http://dx.doi.org/10.2217/epi-2020-0244.

Full text

Abstract:

Aim: This study aimed to identify novel miRNAs (miRs) as regulators of UGT1A gene expression and to evaluate them as potential risk factors for the development of liver fibrosis/cirrhosis. Materials & methods: miRNA target sites in UDP-glucuronosyltransferase 1A (UGT1A) 3′-UTR were predicted and confirmed by luciferase assays, quantitative real-time PCR and western blot using HEK293, HepG2 and Huh7 cells. UGT1A and miRNA expression were analyzed in cirrhotic patients and a mouse model of alcoholic liver fibrosis. Results: miR-214-5p and miR-486-3p overexpression reduced UGT1A mRNA, protein

APA, Harvard, Vancouver, ISO, and other styles

22

Zhang, Geng-lin, Qi-yi Zhao, Chao-shuang Lin, Zhao-xia Hu, Ting Zhang, and Zhi-liang Gao. "Transient Elastography and Ultrasonography: Optimal Evaluation of Liver Fibrosis and Cirrhosis in Patients with Chronic Hepatitis B Concurrent with Nonalcoholic Fatty Liver Disease." BioMed Research International 2019 (January 23, 2019): 1–10. http://dx.doi.org/10.1155/2019/3951574.

Full text

Abstract:

Background and Aims. Concordance between transient elastography (TE) and ultrasonography (US) in assessing liver fibrosis in patients with chronic hepatitis B (CHB) and concurrent nonalcoholic fatty liver disease (NAFLD) has been rarely studied. This study aimed to evaluate the individual and combined performances of TE and US in assessing liver fibrosis and cirrhosis. Patients and Methods. Consecutive CHB patients with NAFLD were prospectively enrolled. TE and US examinations were performed, with liver biopsy as a reference standard. Receiver operating characteristic (ROC) curves were obtaine

APA, Harvard, Vancouver, ISO, and other styles

23

Doan Hieu, Trung, and Chuong Tran Xuan. "LIVER FIBROSIS RESPONSE TO ENTECAVIR TREATMENT IN PATIENTS WITH HBV-RELATED COMPENSATED CIRRHOSIS." Volume 8 Issue 6 8, no. 6 (2018): 203–9. http://dx.doi.org/10.34071/jmp.2018.6.27.

Full text

Abstract:

Background: Evaluating improvement of liver fibrosis response after anti HBV therapy in our country until now is very limited, especially in patients with cirrhosis. This study aimed at assessing the respone in liver fibrosis determined by ARFI and its related factors for patients with compensated HBV-related cirrhosis undergoing entecavir therapy. Subjects and methods: 60 patients with compensated HBV-related cirrhosis were enrolled at Da Nang Hospital from 06/2016 to 06/2018. All received entecavir 0,5mg a day 2 hours after breakfast and followed in 18 months. Liver fibrosis is measured by A

APA, Harvard, Vancouver, ISO, and other styles

24

Turkseven, Saadet, Massimo Bolognesi, Alessandra Brocca, Paola Pesce, Paolo Angeli, and Marco Di Pascoli. "Mitochondria-targeted antioxidant mitoquinone attenuates liver inflammation and fibrosis in cirrhotic rats." American Journal of Physiology-Gastrointestinal and Liver Physiology 318, no. 2 (2020): G298—G304. http://dx.doi.org/10.1152/ajpgi.00135.2019.

Full text

Abstract:

In liver cirrhosis, oxidative stress plays a major role in promoting liver inflammation and fibrosis. Mitochondria dysregulation is responsible for excessive reactive oxygen species production. Therefore, in an experimental model of cirrhosis, we investigated the effect of mitochondria-targeted antioxidant mitoquinone. Liver cirrhosis was induced in Spraque-Dawley rats by common bile duct ligation (CBDL). Mitoquinone (10 mg·kg−1·day−1, oral gavage) or vehicle was administered from 3rd to 28th day after CBDL, when animals were euthanized; liver oxidative stress, inflammation, fibrosis, mitophag

APA, Harvard, Vancouver, ISO, and other styles

25

Wani, Ajaz Ahmed, and Younis Rashid. "Epidemiology of Liver Cirrhosis, Associated Complications and its Management: A Review." Saudi Journal of Medical and Pharmaceutical Sciences 10, no. 08 (2024): 603–7. http://dx.doi.org/10.36348/sjmps.2024.v10i08.013.

Full text

Abstract:

Cirrhosis is characterised by the formation of regenerative nodules in liver parenchyma surrounded by fibrous septa due to chronic liver injury. It occurs due to necrosis of liver cells followed by fibrosis and nodule formation. Cirrhosis is the final stage of chronic liver disease and has many causes including viral hepatitis, excessive alcohol intake and non alcoholic steatohepatitis. Liver cirrhosis effects the quality of life and patient survival. Cirrhotic patients are in need of early diagnosis and careful follow up to prevent further complications.This review article covers the clinical

APA, Harvard, Vancouver, ISO, and other styles

26

Resino, Salvador, Amanda Fernández-Rodríguez, Daniel Pineda-Tenor, et al. "TRPM5 rs886277 Polymorphism Predicts Hepatic Fibrosis Progression in Non-Cirrhotic HCV-Infected Patients." Journal of Clinical Medicine 10, no. 3 (2021): 483. http://dx.doi.org/10.3390/jcm10030483.

Full text

Abstract:

Background: TRPM5 (transient receptor potential cation channel subfamily M member 5) rs886277 polymorphism has been related to liver cirrhosis from different etiologies. The present study investigates the association of TRPM5 rs886277 polymorphism with liver fibrosis progression and cirrhosis development in chronic hepatitis C (CHC) patients. Methods: We conducted a retrospective study of 208 non-cirrhotic patients with CHC, who had at least two liver stiffness measurements (LSM) with a separation of 12 months (baseline LSM (LSM1) and the last LSM (LSM2)). Two outcome variables were considered

APA, Harvard, Vancouver, ISO, and other styles

27

Leung, Daniel H., and Michael R. Narkewicz. "Cystic Fibrosis-related cirrhosis." Journal of Cystic Fibrosis 16 (November 2017): S50—S61. http://dx.doi.org/10.1016/j.jcf.2017.07.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Luerken, Lukas, Marco Dollinger, Andrea Goetz, et al. "Diagnostic Accuracy of Indocyanine Green Clearance Test for Different Stages of Liver Fibrosis and Cirrhosis." Diagnostics 13, no. 16 (2023): 2663. http://dx.doi.org/10.3390/diagnostics13162663.

Full text

Abstract:

(1) Background: This study aimed to correlate the indocyanine green clearance (ICG) test with histopathological grades of liver fibrosis and liver cirrhosis to assess its diagnostic accuracy in differentiating normal liver parenchyma from liver fibrosis and liver cirrhosis. (2) Methods: A total of 82 patients who received a histopathological liver examination, imaging, and ICG test within three months were included in this retrospective study. The histopathological level of fibrosis was graded using the Ishak scoring system, and the patients were divided into five categories: no liver fibrosis

APA, Harvard, Vancouver, ISO, and other styles

29

Basyte-Bacevice, Viktorija, Jurgita Skieceviciene, Irena Valantiene, et al. "SERPINA1 and HSD17B13 Gene Variants in Patients with Liver Fibrosis and Cirrhosis." Journal of Gastrointestinal and Liver Diseases 28, no. 3 (2019): 297–302. http://dx.doi.org/10.15403/jgld-168.

Full text

Abstract:

Background & Aims: Two single nucleotide polymorphisms (SNPs) in SERPINA1 (Pi*Z rs28929474 and Pi*Srs17580) are risk factors for developing liver cirrhosis. A recent study identified a common SNP in HSD17B13(rs72613567) that conferred protection from chronic liver disease. The aim of the present study was to testthese associations in a cohort of Lithuanian patients with liver fibrosis or cirrhosis. Methods: The study included 302 patients with cirrhosis, 127 patients with liver fibrosis (METAVIR stagesI-III) and 548 controls, all from Lithuania. SNPs were genotyped by quantitative PC

APA, Harvard, Vancouver, ISO, and other styles

30

Basyte-Bacevice, Viktorija, Jurgita Skieceviciene, Irena Valantiene, et al. "TM6SF2 and MBOAT7 Gene Variants in Liver Fibrosis and Cirrhosis." International Journal of Molecular Sciences 20, no. 6 (2019): 1277. http://dx.doi.org/10.3390/ijms20061277.

Full text

Abstract:

Previous large-scale genetic studies identified single nucleotide polymorphisms (SNPs) of the TM6SF2 and MBOAT7 genes as risk factors for alcoholic liver cirrhosis and non-alcoholic fatty liver disease. In this study, we tried to evaluate the association between TM6SF2 variant rs58542926 and MBOAT7 variant rs641738 and the risk of hepatic fibrosis or liver cirrhosis of different etiology. In parallel, we also aimed to evaluate whether these two SNPs modify the effects of the PNPLA3 rs738409 risk variant for the development of hepatic fibrosis and liver cirrhosis. The study was conducted at the

APA, Harvard, Vancouver, ISO, and other styles

31

Alzahrani, Mohammed Attieh, Ibrahim Mohammed Almanjahi, Yahia Assiri, et al. "Outcome of Direct-Acting Antiviral Drugs on Treatment of Naïve Cirrhotic and Non-cirrhotic HCV Patients in Assir Region, Saudi Arabia: A Retrospective Cohort Study." Nigerian Journal of Basic and Clinical Sciences 21, no. 3 (2024): 190–95. http://dx.doi.org/10.4103/njbcs.njbcs_93_24.

Full text

Abstract:

Abstract Context: Direct-acting antiviral drugs (DAAs) have revolutionized HCV treatment, but their long-term impact on liver disease severity, fibrosis progression, and hepatocellular carcinoma (HCC) incidence among treatment-naïve cirrhotic and non-cirrhotic patients in Saudi Arabia remains underexplored. This study evaluated the sustained virological response (SVR), liver disease severity, fibrosis progression, and HCC incidence among treatment-naïve cirrhotic and non-cirrhotic HCV patients treated with DAAs in Saudi Arabia. Methods and Materials: A retrospective cohort study was conducted

APA, Harvard, Vancouver, ISO, and other styles

32

Aghemo, Alessio, Maria Grazia Rumi, Roberta Soffredini та ін. "Impaired Response to Interferon-α2B plus Ribavirin in Cirrhotic Patients with Genotype 3A Hepatitis C Virus Infection". Antiviral Therapy 11, № 6 (2005): 797–802. http://dx.doi.org/10.1177/135965350601100602.

Full text

Abstract:

Patients with chronic infection with the 3a genotype of hepatitis C virus (HCV) are considered as ‘easy-to-treat’ with interferon/ribavirin (IFN/RBV), independent of liver disease severity. However, patients with extensive fibrosis or cirrhosis were under-represented in all the registration Phase III trials performed so far. To assess the influence of liver fibrosis on the outcome of anti-HCV therapy, all patients with genotype 3a hepatitis C who were naive to IFN-based therapies, and received RBV combined with standard IFN or pegylated IFN-α2b (peg-IFN-α2b) as standard of care for their disea

APA, Harvard, Vancouver, ISO, and other styles

33

Minanti, Nanda Anessa, and Yusri Dianne Jurnalis. "Hepatic Cirrhosis with Esophageal Varices: A Case Report." Bioscientia Medicina : Journal of Biomedicine and Translational Research 8, no. 7 (2024): 4578–84. http://dx.doi.org/10.37275/bsm.v8i7.1024.

Full text

Abstract:

Background: In adults, portal hypertension is generally caused by hepatic cirrhosis, whereas in children it is more commonly caused by extrahepatic abnormalities with normal liver function. Portal hypertension causes hemodynamic abnormalities. Gastrointestinal bleeding is the most severe clinical manifestation of portal hypertension in both children and adults. Pathogenetically, increased pressure in the portal vein can be caused by increased vascular resistance and increased portal blood flow. The site of obstruction can be prehepatic (portal vein obstruction), intrahepatic (presinusoidal: eg

APA, Harvard, Vancouver, ISO, and other styles

34

Traussnigg, Stefan, Christian Kienbacher, Emina Halilbasic, et al. "Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH." Digestive Diseases 33, no. 4 (2015): 598–607. http://dx.doi.org/10.1159/000375353.

Full text

Abstract:

Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome and comprises a liver disease spectrum ranging from steatosis to nonalcoholic steatohepatitis (NASH) with risk of progression to liver cirrhosis and hepatocellular carcinoma (HCC). Associated metabolic conditions and comorbidities such as obesity, diabetes and cardiovascular diseases are common and require concerted management. Adiponutrin (PNPLA3) variants may help to identify NAFLD patients at higher risk for liver disease progression towards advanced fibrosis and HCC. The therapeutic options in N

APA, Harvard, Vancouver, ISO, and other styles

35

Kim, Youngsung, Jin Woong Kim, Bup Kyung Choi, et al. "Evaluation of the Possible Ameliorative Effects of Anemarrhena asphodeloides Extract on Liver Cirrhosis by Combining Biochemical Analysis and Electrical Tissue Conductivity." Applied Sciences 13, no. 13 (2023): 7950. http://dx.doi.org/10.3390/app13137950.

Full text

Abstract:

Anemarrhena asphodeloides extract (AAE) has been used for the treatment of inflammatory diseases and its anti-inflammatory effects have been reported. In this feasibility study, the hepato-protective effect of AAE was evaluated in a rat liver cirrhosis model by a combination of biochemical analysis and electrical tissue conductivity. Liver cirrhosis was induced by dimethylnitrosamine (DMN) injection. A total of 32 Sprague–Dawley rats were divided into four groups such as normal liver, cirrhotic liver, cirrhotic liver with AAE treatment, and cirrhotic liver with lactulose treatment. Effects of

APA, Harvard, Vancouver, ISO, and other styles

36

Sherman, I. A., S. C. Pappas, and M. M. Fisher. "Hepatic microvascular changes associated with development of liver fibrosis and cirrhosis." American Journal of Physiology-Heart and Circulatory Physiology 258, no. 2 (1990): H460—H465. http://dx.doi.org/10.1152/ajpheart.1990.258.2.h460.

Full text

Abstract:

Quantitative data defining basic microvascular parameters are needed for better understanding of the relationship between liver blood flow and function under normal and pathological conditions. The present study was undertaken to quantitate the following microvascular parameters: flow velocities in sinusoids and terminal hepatic venules; the range of sizes of terminal hepatic vessels; and acinar sizes in both normal rat livers and during the development of liver cirrhosis. Fibrosis and cirrhosis were induced by either weekly administration of carbon tetrachloride (CCl4) or by choline-deficient

APA, Harvard, Vancouver, ISO, and other styles

37

Gaur, S. K., J. C. Vij, S. K. Sarin, and B. S. Anand. "Gastric Secretion in Cirrhosis and Non-Cirrhotic Portal Fibrosis." Digestion 39, no. 3 (1988): 151–55. http://dx.doi.org/10.1159/000199619.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Kupcinskas, Juozas, Irena Valantiene, Greta Varkalaitė, et al. "PNPLA3 and RNF7 Gene Variants are Associated with the Risk of Developing Liver Fibrosis and Cirrhosis in an Eastern European Population." Journal of Gastrointestinal and Liver Diseases 26, no. 1 (2017): 37–43. http://dx.doi.org/10.15403/jgld.2014.1121.261.pnp.

Full text

Abstract:

Background & Aims: Genome-wide association studies have revealed an association between the risk of developing liver fibrosis or cirrhosis and the single nucleotide polymorphisms (SNPs) of the PNPLA3, RNF7, MERTK and PCSK7 genes. We aimed to validate these results in an Eastern European population.Methods: We evaluated the associations between the PNPLA3 (rs738409), RNF7 (rs16851720), MERTK (rs4374383) and PCSK7 (rs236918) variants and liver fibrosis and cirrhosis in a series of consecutive patients recruited at the Department of Gastroenterology, Lithuanian University of Health Sciences H

APA, Harvard, Vancouver, ISO, and other styles

39

Janus, Anita, Dawid Łoś, Agata Kaptur, Dawid Dziedziński, and Aleksandra Nowak. "Guidelines for oncologic surveillance in a patient with established cirrhosis." Quality in Sport 16 (July 8, 2024): 52495. http://dx.doi.org/10.12775/qs.2024.16.52495.

Full text

Abstract:

Cirrhosis is a chronic, diffuse disease process characterized by fibrosis and remodeling of the organ's normal architectonics into regenerative nodules. It is also one of the risk factors for cancers of the organ. One of the most common is hepatocellular carcinoma (HCC). The etiologic agent of HCC, which usually also causes cirrhosis, can be determined in more than 90% of patients. The annual risk of developing HCC ranges from 1% to 8%. It is estimated that about 1/3 of cirrhotic patients will develop HCC. By preventing cirrhosis and controlling its course, we reduce the risk of hepatocellular

APA, Harvard, Vancouver, ISO, and other styles

40

Jin, Young-Joo. "Diagnostic Assessment of Nonalcoholic Fatty Liver Disease." Korean Journal of Medicine 95, no. 5 (2020): 299–307. http://dx.doi.org/10.3904/kjm.2020.95.5.299.

Full text

Abstract:

Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide, and is characterized by fat accumulation at levels exceeding 5% in hepatocytes due to insulin resistance. The disease spectrum ranges from simple nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH)/NASH-related fibrosis or cirrhosis defined by histological findings. Unlike simple NAFL, NASH/NASH-related fibrosis or cirrhosis increases the risk of liver-related morbidity or mortality. Therefore, accurate diagnosis of NASH/NASH-related fibrosis or cirrhosis is needed for management of patients

APA, Harvard, Vancouver, ISO, and other styles

41

Cylwik, Bogdan, Alicja Bauer, Ewa Gruszewska, Kacper Gan, Marcin Kazberuk, and Lech Chrostek. "The Diagnostic Value of FibroTest and Hepascore as Non-Invasive Markers of Liver Fibrosis in Primary Sclerosing Cholangitis (PSC)." Journal of Clinical Medicine 12, no. 24 (2023): 7552. http://dx.doi.org/10.3390/jcm12247552.

Full text

Abstract:

The aim of this study was to evaluate the diagnostic usefulness of two non-invasive, validated, and patented markers of liver fibrosis, the Hepascore and FibroTest, in patients with primary sclerosing cholangitis (PSC). The study group consisted of 74 PSC patients and 38 healthy subjects. All patients had a liver biopsy. The Hepascore and FibroTest were calculated using specific algorithms. The ANOVA rank Kruskal–Wallis test revealed differences in the Hepascore and FibroTest between patients divided according to histological stage (p < 0.001 for both comparisons). The Hepascore and FibroTe

APA, Harvard, Vancouver, ISO, and other styles

42

Maharani, Baiq Nadya Putri, Aulia Dwi Hendriani, and Putu Wika Pramesti Iswari. "Liver Cirrhosis: Pathophysiology, Diagnosis, and Management." Jurnal Biologi Tropis 23, no. 1 (2023): 457–63. http://dx.doi.org/10.29303/jbt.v23i1.5763.

Full text

Abstract:

Liver disease is still a concern in world health and liver cirrhosis is the eleventh leading cause of death in the world. Cirrhosis caused 1.32 million deaths in 2017. Liver cirrhosis is a fibrosis or nodule formation in the liver. The study was conducted on databases, such as PubMed, google scholar and gray literature. With inclusion criteria, that are free full text publications published in 2015-2022 and having relevant discussions. Fibrosis in cirrhosis of liver begins with the activation of Stellate and Kupffer cells, damaged hepatocytes and activated platelets are also invoved. Inflammat

APA, Harvard, Vancouver, ISO, and other styles

43

Pun, Chon Kit, Hui-Chun Huang, Ching-Chih Chang, et al. "Glycyrrhizin Attenuates Portal Hypertension and Collateral Shunting via Inhibition of Extrahepatic Angiogenesis in Cirrhotic Rats." International Journal of Molecular Sciences 22, no. 14 (2021): 7662. http://dx.doi.org/10.3390/ijms22147662.

Full text

Abstract:

Portal hypertension develops along with liver cirrhosis then induces the formation of portal-systemic collaterals and lethal complications. Extrahepatic angiogenesis plays an important role. Glycyrrhizin has been found to exhibit anti-angiogenic features, which leads to its extensive use. However, the relevant effects of glycyrrhizin on liver cirrhosis and portal hypertension have not been evaluated. This study thus aimed to investigate the impact of glycyrrhizin on portal hypertension-related derangements in cirrhotic rats. Male Sprague-Dawley rats received bile duct ligation (BDL) to induce

APA, Harvard, Vancouver, ISO, and other styles

44

Hamdany, Andhika Kusuma, Muhammad Luthfi Parewangi, Sahyuddin Saleh, et al. "Comparison of plasminogen activator inhibitor-1 levels in chronic hepatitis B patients with hepatic cirrhosis and without hepatic cirrhosis." Open Access Macedonian Journal of Medical Sciences 10, B (2022): 2023–28. http://dx.doi.org/10.3889/oamjms.2022.10439.

Full text

Abstract:

Introduction: One of the hepatic cirrhosis manifestations is bleeding disorders. Among all the substance that plays a pivotal role in maintaining the balance between thrombosis and thrombolysis is PAI-1, synthesized by hepatocytes. The dynamics of increase and decrease of PAI-1 is a natural response to the ongoing hepatic cirrhosis, but may not be seen in non-hepatic cirrhosis. PAI-1 levels also depends on the stage of fibrosis. Several conditions may interfere with PAI-1 levels including age, body mass index, and gender Objectives: This study aims to find out the comparison of PAI-1 lev

APA, Harvard, Vancouver, ISO, and other styles

45

Zhu, Mengmei, Tianzhen Hua, Tao Ouyang, Huofu Qian, and Bing Yu. "Applications of Mesenchymal Stem Cells in Liver Fibrosis: Novel Strategies, Mechanisms, and Clinical Practice." Stem Cells International 2021 (August 10, 2021): 1–17. http://dx.doi.org/10.1155/2021/6546780.

Full text

Abstract:

Liver fibrosis is a common result of most chronic liver diseases, and advanced fibrosis often leads to cirrhosis. Currently, there is no effective treatment for liver cirrhosis except liver transplantation. Therefore, it is important to carry out antifibrosis treatment to reverse liver damage in the early stage of liver fibrosis. Mesenchymal stem cells (MSCs) are the most widely used stem cells in the field of regenerative medicine. The preclinical and clinical research results of MSCs in the treatment of liver fibrosis and cirrhosis show that MSC administration is a promising treatment for li

APA, Harvard, Vancouver, ISO, and other styles

46

Pradhan, SV. "Redefining Cirrhosis – a brief review." Journal of Pathology of Nepal 3, no. 6 (2013): 491–96. http://dx.doi.org/10.3126/jpn.v3i6.9000.

Full text

Abstract:

The liver damage is associated with variable amount of fibrosis. The presence of fibrosis with nodule formation is pathognomic of cirrhosis. It is accompanied by vascular remodeling and regeneration with important functional and hemodynamic consequences that include development of portal hypertension and eventually decompensation and death. However fibrosis can regress following successful treatment of the underlying disease. The classification system followed till date does not analyze this aspect. In this brief review the histological features of fibrosis and the newer models for reclassifyi

APA, Harvard, Vancouver, ISO, and other styles

47

Ekta, A. Andriyas, Kushwaha Neetu, Pant Neha, et al. "A systematic review on contemporary serum biomarkers for predicting liver fibrosis." World Journal of Advanced Research and Reviews 23, no. 3 (2024): 082–88. https://doi.org/10.5281/zenodo.14908987.

Full text

Abstract:

Excessive extracellular matrix (ECM) deposition in the liver is a hallmark of liver fibrosis, a basic pathological process in the majority of chronic liver disorders (CLD). It is basically a reversible wound-healing reaction that is accompanied by liver parenchymal cell necrosis and apoptosis. Tissue scarring brought on by the progressive build-up of extracellular matrix (ECM) eventually leads to cirrhosis, portal hypertension, and liver failure. After at least 15–20 years of chronic liver parenchymal injury, progressive fibrogenesis, chronic inflammation, and persistent liver injury int

APA, Harvard, Vancouver, ISO, and other styles

48

Somnay, Kaumudi, Priyanka Wadgaonkar, Nidhishri Sridhar, Prarath Roshni, Nachiketh Rao, and Raj Wadgaonkar. "Liver Fibrosis Leading to Cirrhosis: Basic Mechanisms and Clinical Perspectives." Biomedicines 12, no. 10 (2024): 2229. http://dx.doi.org/10.3390/biomedicines12102229.

Full text

Abstract:

Liver fibrosis is the pathological deposition of extracellular matrix rich in fibrillar collagen within the hepatocytes in response to chronic liver injury due to various causes. As the condition advances, it can progress to cirrhosis, the late stages of which are irreversible. Multiple pathophysiological mechanisms and cell types are responsible for the progression of liver fibrosis and cirrhosis. Hepatic stellate cells and myofibroblast activation represent a key event in fibrosis. Capillarization of liver sinusoidal endothelial cells further contributes to extracellular matrix deposition an

APA, Harvard, Vancouver, ISO, and other styles

49

Little, D. H., S. Fischer, and S. K. Fung. "A209 NON-INVASIVE ASSESSMENT OF LIVER FIBROSIS USING APRI, FIB-4, AND TRANSIENT ELASTOGRAPHY IN CHRONIC HEPATITIS B PATIENTS." Journal of the Canadian Association of Gastroenterology 4, Supplement_1 (2021): 239–40. http://dx.doi.org/10.1093/jcag/gwab002.207.

Full text

Abstract:

Abstract Background Accurate assessment of liver fibrosis is important to identify patients with chronic hepatitis B (CHB) who require antiviral therapy. As liver biopsy is invasive and costly, non-invasive tests of liver fibrosis are increasingly being used. Aims We aimed to evaluate the performance of the aspartate aminotransferase-to-platelet ratio index (APRI), Fibrosis 4 index (FIB-4), and transient elastography (TE) in predicting fibrosis in patients with CHB. Methods We retrospectively analyzed a prospectively enrolled cohort of consecutive adults with CHB who underwent liver biopsy for

APA, Harvard, Vancouver, ISO, and other styles

50

Nishikawa, Koji, Yosuke Osawa та Kiminori Kimura. "Wnt/β-Catenin Signaling as a Potential Target for the Treatment of Liver Cirrhosis Using Antifibrotic Drugs". International Journal of Molecular Sciences 19, № 10 (2018): 3103. http://dx.doi.org/10.3390/ijms19103103.

Full text

Abstract:

Cirrhosis is a form of liver fibrosis resulting from chronic hepatitis and caused by various liver diseases, including viral hepatitis, alcoholic liver damage, nonalcoholic steatohepatitis, and autoimmune liver disease. Cirrhosis leads to various complications, resulting in poor prognoses; therefore, it is important to develop novel antifibrotic therapies to counter liver cirrhosis. Wnt/β-catenin signaling is associated with the development of tissue fibrosis, making it a major therapeutic target for treating liver fibrosis. In this review, we present recent insights into the correlation betwe

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!